Critically, exogenous re-introduction of Wnt pathway inhibitors, such as sFRP1, 2 or 5 and Dkk1, or reversing promoter methylation can significantly limit and reduce in vitro tumourgenicity and tumour xenograft burden of Wnt pathway-activated gastric cancer models by means of attenuating Wnt/β-catenin signalling [81,177,178]. Here, SFRP1 is linked to neoplasm.